Sareum Holdings PLC on Friday celebrated a new patent allowance for SDC-1801, which is a therapy designed to treat a range of autoimmune diseases.

According to the Cambridge, England-based pharmaceutical company, the European Patent Office has issued a notice of allowance for a patent relating to SDC‐1801. The patent, EP3864009, safeguards SDC‐1801 and its medical applications, particularly in terms of treating autoimmune diseases, and certain methods of synthesis.

Sareum recently received approvals for the same protections from the China National Intellectual Property Administration, and the Japan Patent Office. Applications in the US are still under review.

The firm expects the patent to be granted in the near future, ‘subject to certain formalities’.

‘This new patent allows us to enhance our intellectual property portfolio in a crucial market. Our Phase 1a trial for SDC-1801 in Australia is progressing smoothly, with the Single Ascending Dose (SAD) and Food Effect study revealing no significant adverse events. This progress highlights the potential of SDC-1801 to achieve therapeutic drug levels in the bloodstream through once-daily oral dosing,’ said Chief Scientific Officer John Reader.

Sareum Holdings shares were trading 1.1% lower at 23.74 pence each in London on Friday morning.

Copyright 2024 Alliance News Ltd. All Rights Reserved.